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SUMMARY
Context-specific molecular vulnerabilities that arise during tumor evolution represent an attractive
intervention target class. However, the frequency and diversity of somatic lesions detected among
lung tumors can confound efforts to identify these targets. To confront this challenge, we have
applied parallel screening of chemical and genetic perturbations within a panel of molecularly
annotated NSCLC lines to identify intervention opportunities tightly linked to molecular response
indicators predictive of target sensitivity. Anchoring this analysis on a matched tumor/normal cell
model from a lung adenocarcinoma patient identified three distinct target/response-indicator
pairings that are represented with significant frequencies (6–16%) in the patient population. These
include NLRP3 mutation/inflammasome activation-dependent FLIP addiction, co-occuring KRAS
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and LKB1 mutation-driven COPI addiction, and selective sensitivity to a synthetic indolotriazine
that is specified by a 7-gene expression signature. Target efficacies were validated in vivo, and
mechanism of action studies uncovered new cancer cell biology.
INTRODUCTION
Widespread evidence indicates that aberrant cancer cell regulatory frameworks generate
collateral vulnerabilities that can be exploited for therapeutic benefit. These vulnerabilities
can be a consequence of oncogene addiction, gene-specific haploinsufficiencies, and other
genetically and epigenetically-derived fragilities in cell regulatory systems (Janne et al.,
2009; Luo et al., 2009; Muller et al., 2012). The critical barrier confronting this opportunity,
for many tumor types, is the extreme heterogeneity of the molecular etiology of neoplastic
disease, which confounds annotation of effective context-selective intervention targets. For
non-small cell lung cancer (NSCLC), a tumor responsible for 1 million deaths/year, over
160 nonsynomous somatic mutations are detected per tumor, the vast majority of which are
non-recurrent (Cancer Genome Atlas Research, 2012; Imielinski et al., 2012). Actionable
mutations have been identified in EGFR and EML4-ALK (Lynch et al., 2004; Soda et al.,
2007) but are present in only 15% of lung adenocarcinomas (Imielinski et al., 2012) while
the majority of NSCLC patients are not associated with any known pharmaceutically
addressable target. This missing coverage underscores the need to develop new target
opportunities that are tightly linked to molecular response indicators.
To generate a testbed representative of the molecular heterogeneity of non-small cell lung
cancer, we assembled a panel of 91 lung tumor-derived cell lines and 3 immortalized
nontumorigenic airway epithelial cultures. Though limited by the sparse complexity of the
tissue culture environment and therefore limited in the synthetic genetic and chemical
interactions that can be observed, this cell line panel has been shown to recapitulate genetic
profiles found in tumors, and to recapitulate selective responsiveness to molecularly targeted
therapies (Gazdar et al., 2010; Sharma et al., 2010). Beginning with a matched tumor/normal
cell model from a single lung adenocarcinoma patient, 230,000 synthetic small molecules
and two independent whole-genome arrayed siRNA libraries were used to identify chemical
and genetic perturbations selectively toxic to the patient’s tumor cell line. These agents were
then tested to identify perturbations that were innocuous to non-tumorigenic cells, but which
had activity in at least 30% of the NSCLC cell lines. The resulting toxicity patterns were
correlated with genomic profiles to identify somatic mutations and expression signatures
that predicted sensitivity or resistance to these perturbations. In this way, we identified 3
distinct target/response-indicator pairings. First, we found that NLRP3 mutations, which
occur in 16% of lung adenocarcinomas, drive addiction to the anti-apoptotic protein FLIP.
The mechanism of action is through NLRP3-dependent chronic activation of inflammasome
signaling, which sensitizes these cells to FLIP-dependent restraint of caspase 8-induced cell
death. Second, we found that co-occurring mutations in KRAS and LKB1, present in 6% of
lung adenocarcinoma patients, are sufficient to drive addiction to COPI-dependent lysosome
acidification. This liability was determined to be a consequence of obligate supply of TCA-
cycle substrates by lysosome-dependent consumption of extracellular macromolecules.
Chemical inhibition of this process, with the natural product saliphenylhalamide A, inhibited
KRASmut/LKB1mut tumor cell survival in vitro and in vivo. Finally, we found that selective
sensitivity to a synthetic indolotriazine defines a subtype of NSCLC cells estimated to occur
at a frequency of ~10% of lung tumors. Indolotriazine-sensitivity corresponded to selective
activation of an endoplasmic reticulum stress response and can be effectively predicted
using a 7-gene quantitative mRNA expression signature.
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RESULTS
Public and Private Vulnerabilities in NSCLC
To begin to assess the diversity of selective vulnerabilities that can arise within lung cancer
cell autonomous regulatory contexts, we selected a matched tumor/normal pair (HCC4017/
HBEC30KT), derived from a 62-year-old female smoker with stage 1A adenocarcinoma, for
extensive functional and genomic interrogation (Figure 1A). Authentic somatic mutations
and copy number variation, in the tumor line as compared to normal cells, were identified
from whole-exome hybridization-capture sequencing (130X average read-depth, Table S1,
Data S1). 296 nonsynonymous exonic single nucleotide somatic variants were detected in
HCC4017 (Figure 1B), 152 of which are predicted to be deleterious to protein function
(Data S1). Copy number variation was extensive, as estimated by exon read-depth (Figures
1B and S1A) and SNP array (Figure S1A), and correlated with relative mRNA
concentrations as determined by RNA-seq (Data S2, Figure S1A). Two whole genome
arrayed siRNA libraries, and a collection of ~230,000 chemical compounds were then
screened to identify agents selectively toxic to HCC4017 versus HBEC30KT (Data S2 and
S3).
A Z-score cutoff of -3 was used to identify candidate HCC4017-selective siRNA
sensitivities. This thresholding resulted in predominantly non-overlapping sets of candidates
from each siRNA library, presumably due to a combination of false negative and false
positive relationships. As previously described (Jacob et al., 2011), the former is at least
partially an artifact of assigned selection thresholds. In direct support of this, the empirical
cumulative distribution of the Z-scores from siRNA pools in library 1, corresponding to
“hits” from library 2, indicated a significant enrichment of activity as compared to the
background distribution (Figure S1B). To defend against false positives, individual oligos
were tested for each of the 326 non-redundant “hits” from the union of the two libraries
together with a KS statistic that predicts oligonucleotide seed sequence-specific activity that
is independent of target depletion (Tables S2 and S3, Data S4). 85 surviving siRNA pools,
that were reproduced in HCC4017 and also innocuous upon testing in HBEC30KT and 2
additional telomerase/CDK4-immortalized nontumorigenic HBEC lines, were then
examined across a panel of 21 additional NSCLC cell lines (Data S5, Figures 1C and S1C).
A striking feature of the response of the cell line panel to the siRNA collection was the
largely idiosyncratic activity pattern (Figure 1C). 40% of the tested siRNAs had measurable
consequences on the viability of 10% or less of the cell line panel, and no single siRNA pool
was identified with activity in over 90% of the panel (Data S5, Figure 1C). Manual curration
of the biological processes served by the siRNA target genes indicated an enrichment of
signal transduction machinery and transcription factors within the “private” target class and
an enrichment of house-keeping machines (cell cycle control, mRNA splicing, ribosomal
proteins, and vesicle trafficking) within the “public” target class (Data S6, Figure 1D).
Among the private targets, small molecule inhibition of USP8 (Guedat and Colland, 2007)
largely recapitulated the selectivity of siRNA-mediated USP8 depletion- suggesting bona
fide selectivity (Figure S1D). We found significant correlation of the private target class of
HCC4017-sensitive siRNAs with low target gene expression, suggesting the private nature
of some targets may be at least partially a consequence of expression bias (Figure S1E). As a
whole, siRNA targets were recovered evenly from all genomic loci with the exception of
homozygously deleted regions where, as expected, none were located (Figures 1B and S1F).
However, a slightly larger number of “hits” (CACNA2D4, POM121L12, TMEM106B,
BZW2, RBBP9, HBA1, NUPL2, SDK1, VSTM2A, C16orf54, and CYC1) were identified
from amplified and overexpressed loci as compared to the rest of the genome (Figures S1F
and S1G). A first-degree interaction network was constructed to identify potential coherent
relationships among HCC4017-selective targets and the somatic mutations detected within
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that cell line (Figure S1H). Though verifiable and informative relationships were detected
(Figures S1I and S1J), direct connections to somatic variation appear insufficient to account
for the high frequency of private vulnerabilities identified within this cell line.
Context-selective FLIP-addiction
We prioritized relationships found in at least 30% of the NSCLC panel to afford an
opportunity for co-detection of genetic response indicators. Depletion of CFLAR, which
encodes the catalytically inactive Caspase 8 analog FLIP (Irmler et al., 1997), was sufficient
to markedly induce apoptosis in HCC4017 cells and was toxic to multiple additional
NSCLC lines as compared to non-tumorigenic bronchial epithelial cells (Data S5, Figure
S1C). Cell lines from the two tails of the toxicity profile, derived from testing CFLAR
depletion in 22 NSCLC lines, were selected for interrogation of molecular features
correlating with sensitivity to CFLAR depletion (Figure 2A). From whole-genome mRNA
expression profiles, PYCARD, IFIT2 and IFIT3 were identified as the top ranked genes
commonly upregulated in CFLAR-dependent versus CFLAR-independent cell lines (Figure
2A bottom panel). This expression model was sufficient to predict additional CFLAR-
dependent cell lines from an unsupervised hierarchical cluster of a panel of 34 lines outside
the original discovery set (Figure S2A). FLIP restrains execution of programmed cell death
pathways through direct suppression of caspase 8 (Tschopp et al., 1998). FLIP addiction
therefore infers the presence of latent death signals that are released upon removal of
prosurvival restraints. This scenario is akin to the selective sensitivity of cancer cells to
chemical mimics of SMAC (second mitochondria-derived activator of caspase) in the
presence of TNF-dependent apoptotic signaling; which is the consequence of uncoupling
IAP (inhibitor of apoptosis) proteins from otherwise active Caspases (Tenev et al., 2011).
However, only 2 of 7 FLIP-dependent cell lines examined were additionally sensitive to
SMAC-mimic exposure, suggesting FLIP can restrain programmed cell death signals
independently of SMAC-responsive IAPs (Figure 2A, Table S4). FLIP-dependence did not
correlate with expression of FLIP, its pro-death partner Caspase 8, or SMAC-mimic
resistant IAP2 (Petersen et al., 2010) (Figure S2B). However, sensitivity to FLIP depletion
was completely reversed upon Caspase 8 codepletion (Figure 2B). In contrast, SMAC-
mimic sensitivity was minimally affected by Caspase 8 depletion, and completely reversed
by depletion of RIP1 kinase, an initiator of ripoptosome assembly that is negatively
regulated by IAPs (Feoktistova et al., 2011; Tenev et al., 2011) (Figure 2C). Rescue of FLIP
addiction by depletion of individual core components of the ripoptosome, or other canonical
death pathway activators implicated in cancer, was cell-line selective (Figure 2B). This
suggests that multiple distinct regulatory contexts within the NSCLC panel converge on
FLIP-dependent restraint of Caspase 8-initiated cell death. By its nature, the PYCARD,
IFIT1, IFIT2 expression signature is serving as a common indicator of these distinct
contexts (Figure 2A). IFIT1 and 2 are primary response genes induced by interferon, and
may ordinarily mediate cytotoxic responses to pathogen detection (Wathelet et al., 1988).
PYCARD encodes ASC, a component of the inflammasome whose expression is also
responsive to inflammasome activation signals (Masumoto et al., 2006; Strowig et al.,
2012). Of note, HCC4017 harbors a somatic nonsense mutation in the inflammasome
component NLRP3 located in the linker region between the N-terminal NACHT domain and
C-terminal LRR (leucine-rich repeat) domain (p.Y591*, Figure 2D). This alteration is
predicted to encode a truncated constitutively active protein, due to loss of LRR-domain
mediated repression of the NACHT domain (Hu et al., 2013). Derepression of NACHT
domains promotes promiscuous NALP oligomerization and interaction with CARD domain
proteins like ASC (Strowig et al., 2012). Somatic exonic NLRP3 mutations are present in
16% of lung adenocarcinomas (Figure S2C, 21/129 in the LUAD TCGA samples)(Cerami et
al., 2012) and NLRP3 mutant adenocarcinomas were significantly enriched for NFκB
activity (Figure S2D), suggesting NLRP3 mutations in this context may be gain of function
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alterations. In support of this, highly deleterious mutations in NLRP3 are significantly
associated with PYCARD overexpression within the TCGA adenocarcinoma dataset (Figure
2E) and there is an overall significant positive correlation between PYCARD and NLRP3
expression (Figure S2E). Targeted sequencing revealed an analogous nonsense mutation in
the FLIP-dependent cell line HCC15 (p.E401*) and a missense mutation in the FLIP-
dependent cell line HCC366 (p.S727Y)(Barretina et al., 2012). Importantly, like Caspase 8,
codepletion of NLRP3 relieved sensitivity of NSCLC lines to FLIP depletion, suggesting
NLRP3 activity helps drive FLIP addiction (Figure 2F). Furthermore, NLRP3 mutation
status was significantly associated with sensitivity to FLIP depletion (Figure S2F) and two
additional NLRP3 mutant NSCLC lines, identified from outside of the original tested panel,
were also FLIP-dependent (Figure S2G).
To model conservation of Flip addiction within a tumorigenic context, we assessed the
effects of CFLAR knock-down in a mouse xenograft model. Two weeks following
subcutaneous injection of HCC15 cells, mice were randomly divided and treated with
siRNAs incorporated into DOPC nanoliposomes (i.p. administration) according to the
following treatment groups (n = 10/group): control siRNA/DOPC and CFLAR siRNA/
DOPC for four weeks. In comparison to the control siRNA group, tumors from the CFLAR
siRNA group had a 87.2% reduction in tumor mass (p = 0.026, Figure 2G). These
cumulative observations indicate FLIP may represent an intervention opportunity in lung
cancer linked to enrollment biomarkers that include NLRP3 mutation status.
KRAS/LKB1 mutation status specifies Coatomer 1 addiction
Next, the mutation status for 5 recurrently mutated genes (TP53, CDKN2A, KRAS, STK11
(LKB1), NRAS), collected by targeted sequencing, was queried for association with each of
85 siRNA toxicity profiles (Table S1, Data S5). Of note, co-occurrence of KRAS/LKB1
mutations was significantly associated with sensitivity to depletion of COPI subunits
ARCN1, COPB1, and COPA (Figure S3A). Approximately 6% of lung adenocarcinoma
patients have co-occurring KRAS/LKB1 mutations (Imielinski et al., 2012). COPI
participates in retrograde transport, is required for endosome maturation (Huotari and
Helenius, 2011; Razi et al., 2009), and is a CDC42 effector required for CDC42
transformation (Wu et al., 2000). From the intersection of the first-degree interaction
network of HCC4017-essential genes (Figure S1H) and the commonality of responsiveness
with the larger NSCLC cell line panel (Figures 1C and 1D), we identified a total of 5 of 7
components of the coatomer complex I (COPI). NSCLC cell lines representing the two tails
of the distribution of sensitivity to COPI subunit depletion are shown in Figure 3A.
Inhibition of COPI expression in multiple telomerase-immortalized bronchial epithelial cells
was relatively innocuous, and comparable to the consequence of COPI depletion in the
COPI-resistant cancer lines (Figures 3A and 3B). Sensitivity to COPI depletion was
recapitulated in soft agar colony formation assays (Figure 3C). To assess the therapeutic
utility of targeting the COPI subunit ARCN1, we utilized an orthotopic lung
adenocarcinoma model capable of spontaneous metastasis. One week following surgical
introduction of A549 cells into the left lung, mice were randomly divided and treated with
siRNAs incorporated into DOPC nanoliposomes (i.p. administration) according to the
following treatment groups (n = 10/group): control siRNA or ARCN1 siRNA for 5 weeks.
Treatment with ARCN1 siRNAs led to substantial reductions in primary tumor size (92.9%
by volume, p = 0.0087; 51.3% by left lung mass, p=0.0032) as well as metastastic burden
(90.4% reduction, p = 0.0015) (Figure 3D and S3B). This sensitivity correlated with
hypophosphorylation of Rb and induction of cell cycle arrest and apoptosis in vitro (Figures
S3C and S3D). HCC4017 was an outlier with respect to LKB1 mutation status, however,
this line has a defective AMPK response and therefore is the functional equivalent of COPI-
addicted cell lines with compound lesions in KRAS and LKB1 (Figure 3E). Importantly, co-
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occurrence of KRAS and LKB1 mutations was a robust predictor of COPI-addiction when
tested in NSCLC cell lines outside the original discovery panel (Figure 3F), and LKB1-
depletion was sufficient to sensitize KRAS mutant/LKB1 wild-type cell lines to COPI-
depletion (Figure 3G).
Oncogenic KRAS together with LKB1 loss is sufficient to induce COPI-addiction
To evaluate the sufficiency of compound KRAS and LKB1 perturbation for induction of
COPI-addiction, we engineered a series of HBEC30KT derivatives with stepwise stable
suppression of p53, stable expression of KRASG12V, and stable suppression of LKB1
(Figures 4A, S4A, and S4B). Among these, only the final derivative was tumorigenic in
immune-compromised mice, and tumors presented with mixed adeno/squamous
characteristics (Figure 4B). This mixed morphology is strikingly similar to that observed in
spontaneous mouse lung tumors that arise as a consequence of KrasG12V expression in an
Lkb1 null background (Ji et al., 2007). A screen of 85 siRNA pools corresponding to the
HCC4017-essential genes, within the HBEC30KT isogenic progression series, revealed
acquired vulnerability to 17 targets within the KRASmut/LKB1mut background (Figure 4C).
Sensitivity to depletion of these same 17 genes was significantly enriched in KRASmut/
LKB1mut NSCLC cell lines as compared to other NSCLC lines tested (Figure 4D). COPI
subunits were present in this context, indicating that KRASmut/LKB1mut status is sufficient
to specify COPI-addiction (Figure 4E).
The KRASmut/LKB1mut NSCLC subtype mirrors the mesenchymal (Claudin-low) subtype of
triple negative breast cancer
Gene set enrichment analysis of whole-genome transcript profiles from COPI-sensitive
versus COPI-resistant cell lines returned EMT, NFκB and tryptophan metabolism as
significantly associated with KRASmut/LKB1mut status (Table S5, Figure S5A, nominal p <
0.01), though none of these signatures cleanly segregated the two classes. An siCOPI
toxicity associated gene expression signature, with bimodal distribution, returned a more
focused separation centered on chemokines and cytokines (Figure S5B, FDR < 0.001)
reminiscent of the oncogenic RAS-induced secretory senescence phenotype (Coppe et al.,
2008). Remarkably, 30% of the top 100 most differentially expressed genes, as defined by
signal to noise ratio, intersected the molecular classification signature for the mesenchymal,
or “claudin low”, subtype of triple negative breast cancer (Prat et al., 2010) (Figure 5A,
hypergeometric p < 6.7 X 10E-16). Consistent with this, we found that 3 “claudin-low”
breast cancer cell lines (Prat et al., 2010) were sensitive to COPI depletion as compared to
cell lines corresponding to the luminal A or basal A subtypes (Figure 5B). The mesenchymal
subtype of triple-negative breast cancer is an aggressive metastatic disease enriched with
self-renewing tumor-initiating cells (Prat et al., 2010). Dichotomization of 272 molecularly
and clinically annotated lung tumor samples, using the expression signature defined by
COPI-addiction, revealed significantly reduced overall survival and disease-free survival for
patients harboring signature-positive tumors (Figures 5C and S5C). Importantly, this
relationship was reproducible with an independent patient cohort and data set (Figure S5D).
To parse molecular correlates that may provoke COPI-addiction, we employed a focused
suppressor screen that queried genes and pathways enriched in the COPI-sensitive cell lines
(Figures S5E and S5F; see methods for rationale). The most significant interaction recovered
was IL-6 pathway activation (Figure S5E). IL-6 secretion was significantly elevated in the
COPI-sensitive lung and breast cancer cell lines, including the HBEC30KT progression
series (Figures S5G, S5H, and S5I). Oncogenic RAS expression was sufficient to induce
IL-6 production, however, co-occurring loss of LKB1 signaling enhanced this phenotype in
human epithelial cells and in mouse tumors (Figures S5I, S5J, and S5K). Inhibition of IL-6
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signaling by IL-6 depletion, IL-6R depletion, or Let-7 expression, significantly suppressed
COPI-addiction (Figures 5D, 5E, 5F, and S5L).
IL-6 has been characterized as a RAS-responsive cytokine that promotes tumorigenesis in a
paracrine fashion by provoking stromal remodeling of the tumor microenvironment (Coppe
et al., 2008). Consistent with this, we found IL-6 secretion was KRAS-dependent in COPI-
addicted cell lines (Figure 5G). Furthermore, the tryptophan metabolism expression
signature associated with COPI-addicted (KRASmut/LKB1mut) cell lines (Figure S5A)
implicated aryl hydrocarbon receptor (AhR) signaling as a mechanism that may contribute
to IL-6 production. AhR induces IL-6 production in metastatic glioma and both kynurenine
and kynurenic acid, produced during tryptophan synthesis, serve as endogenous AhR ligands
(Opitz et al., 2011). Consistent with this, depletion of AhR or the AhR nuclear translocator
(ARNTL) significantly reduced IL-6 secretion (Figure 5H). Taken together these
observations suggest that selection for IL-6 secretion within the tumor microenvironment
has collateral consequences on tumor cell biology that provoke addiction to COPI function.
COPI activity thus becomes a collateral vulnerability that, if targetable, may represent a
precision intervention opportunity.
Lysosomal maturation is required to support mitochondrial oxidative phosphorylation and
survival of KRASmut/LKB1mut NSCLC cells in vitro and in vivo
LKB1/AMPK-dependent repression of acetyl-CoA carboxylases (ACC1/2) can deflect
catastrophic accumulation of oncogenic RAS-induced reactive oxygen species in cultured
cells. This is thought to occur by limiting consumption of NADPH by ACC for fatty acid
synthesis, which in turn increases the NADPH/NADP+ ratio needed to maintain the cellular
redox state (Jeon et al., 2012; Son et al., 2013). This presents a compelling mechanistic
scenario whereby KRASmut/LKB1mut cells are selectively sensitized to perturbations that
impair reduction of reactive oxygen. In contradiction to this expectation we found that
glutathione or N-acetyl cysteine failed to rescue COPI-addiction, and were instead
individually toxic (Figures S5F). Furthermore, the free radical scavenger NDGA displayed
synthetic toxicity to KRASmut/LKB1mut expression in the HBEC30KT background,
consistent with the reported prosurvival role of reactive oxygen within the context of
oncogenic RAS expression (Figure S6A) (Irani et al., 1997).
To help uncover the mechanistic basis of COPI-addiction we assembled a panel of chemical
probes that 1) intersect biological processes coupled to COPI function, 2) inhibit signaling
pathways dysregulated in the KRASmut/LKB1mut background, or 3) engage cell stress
responses predicted to be induced by COPI depletion. The dose-dependent toxicity response
to these compounds was then measured across 20 cell lines. Within this panel, the vacuolar
ATPase inhibitor bafilomycin A1 (bafA) was discovered to have significant selective
toxicity against the KRASmut/LKB1mut cell lines (Figure 6A) independent of ROS (Figure
S6B and S6C). Like COPI-depletion, exposure to 50 nM bafA for 48 hours induced CDKI
accumulation, Rb hypophosphorylation and caspase activation (Figure S6D). This suggests
that KRASmut/LKB1mut cells may be selectively dependent upon lysosomal maturation
which is itself dependent upon COPI complex activity (Huotari and Helenius, 2011; Razi et
al., 2009). A comparison of steady-state organelle accumulation revealed dramatic
enrichment of acidic lysosomes in KRASmut/LKB1mut cells as compared to COPI-
insensitive cells (Figure S6E). Furthermore, gain of COPI dependency through LKB1
depletion in a KRAS mutant NSCLC line, H2009, was coupled to the accumulation of the
lysosomal membrane protein, LAMP2 (Figure S6F). The elevated lysosomal activity in
KRASmut/LKB1mut cells was reversed upon COPI subunit depletion independently of
detectable morphological perturbation of the golgi (Figures 6B and S6G), and by
concentrations of bafA, below those required to inhibit lysosomal acidification of non
KRASmut/LKB1mut NSCLC cells (Figure S6H). A gene expression feature (top ranked GO
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term by GSEA) associated with COPI dependency and KRASmut/LKB1mut status was the
enrichment of energy derivation by oxidation (Table S5, Figure S6I). Related to this, we
noted that COPI depletion, exposure to bafA, or exposure to a structurally distinct vATPase
inhibitor, saliphenylhalamide A (saliPhe)(Lebreton et al., 2008), resulted in the concomitant
appearance of dysmorphic mitochondria in KRASmut/LKB1mut cells (Figures 6B and 6C)
but not in bafA-resistant cells (Figure S6J). This altered morphology corresponded to
reduced oxygen consumption rates together with increased extracellular acidification rates,
suggesting impaired oxidative phosphorylation and concomitant induction of glycolysis
(Figures 6D and S6K). However, this mitochondrial dysfunction was not coupled to loss of
mitochondrial membrane potential (Figure S6L). Rather, bafA and saliPhe inhibited
incorporation of heavy carbons from C13-labelled glucose or glutamine into citrate,
consistent with inhibition of the mitochondrial TCA-cycle (Figure 6E).
Perhaps through a futile adaptive response, loss of TCA cycle activity was paralleled by
increased glucose and glutamine consumption concomitant with conversion to secreted
lactate and glutamate (Figure S6M and S6N). This phenotype was also observed in response
to COPI depletion (Figure S6O). Finally, we found that direct inhibition of vATPase
assembly by ATP6V1B2 depletion was sufficient to prevent lysosomal acidification (Figure
6F) and inhibit mitochondrial respiration (Figure 6G). These observations indicate
lysosomal maturation is selectively required to support mitochondrial function in KRASmut/
LKB1mut cells. The coupling of this vulnerability to a genetic background that promotes
energetic stress led us to consider the possibility that KRASmut/LKB1mut cells are
selectively dependent upon hydrolysis of lysosomal macromolecules for supply of
mitochondrial TCA cycle substrates. We found that delivery of cell permeable pyruvate
(methyl pyruvate, MP) or alpha-keto-glutarate (dimethyl-2-oxoglutarate, MOG), two major
carbon sources fueling mitochondrial TCA cycle, rescued cell viability and mitochondrial
respiration in the presence of bafA (Figures 6H and S6P). Importantly, this rescue occurred
without restoration of lysosomal acidification (Figure S6Q), consistent with the hypothesis
that lysosomes support mitochondrial function through supply of an obligate nutrient source
in KRASmut/LKB1mut cells. Perdurant acetyl-CoA carboxylase activity in the KRASmut/
LKB1mut background is likely a mechanism that helps drive lysosomal addiction, as ACC1
depletion rescued cell viability in the presence of bafA (Figure 6I). We suspect that ACC1
inactivation is facilitating productive fatty acid beta-oxidation as an alternate energy source
due to depletion of malonyl-coA, an ACC1 product that inhibits mitochondrial import of
long chain fatty acids (Abu-Elheiga et al., 2001). These observations present a compelling
argument for consideration of lysosomes as a metabolic bottleneck by which to target energy
homeostasis in KRASmut/LKB1mut lung cancer cells. To model this in vivo, mice bearing
established HCC4017 subcutaneous xenografts were exposed to SaliPhe (12.5 mg/kg/day, n
= 5) or vehicle (n = 4) using osmotic pumps implanted ip. The pumps eluted drugs for ~17
days at which time, tumors in the vehicle treated group were 174% larger while tumors in
the SaliPhe treated animals were 40% of the starting volume. The effect of SaliPhe was
durable as tumors were allowed to grow for an additional 35 days in the absence of further
drug exposure and tumors in SaliPhe treated animals were 4-fold smaller than tumors in
vehicle treated animals (0.116 +/− 0.27 g vs. 0.46 +/− 0.13 g; p < 0.05) (Figure 6J).
A gene expression model predicts sensitivity to a synthetic compound, indolotriazine
To collect additional chemical probes for detection of subtype-selective vulnerabilities in
NSCLC, we examined 352 compounds (out of 230,000 screened) that were selectively toxic
to HCC4017 cells versus HBEC30KT at 2.5 μM (Figure S7A, Data S3–1 and S3–2). 2 of the
352 compounds displayed bimodal LD50s across 12 NSCLC lines (> 3 fold separation of
“sensitive” vs. “resistant” lines). Among these, an indolotriazine, SW044248, was
selectively toxic in 18/74 NSCLC lines and innocuous up to the highest testable dose in 4
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different telomerase immortalized bronchial epithelial cell lines (Figure 7A, Data S3–3). To
inform the mode of action, resistant HCC4017 subclones were isolated following long-term
exposure to the compound. RNA-seq identified differential gene expression responses to
SW044248, in parental versus resistant HCC4017 variants, corresponding to a strong and
selective ER stress response signature (Figure 7B, Data S7)(Hetz, 2012). Consistent with
this, CHOP and IRE1α were robustly induced within 24 hours of exposure to SW044248
(Figure 7C). This response was uniform among the SW0448248-sensitive NSCLC lines but
absent in resistant lines (Figure 7D). The latter is most likely a consequence of selective
vulnerability rather than selective exposure as equivalent SW044248 accumulation and
stability was observed in both sensitive and resistant cell lines as detected by GCMS
(Figures S7B and S7C).
To identify features that may predispose to the indolotriazine-sensitivity, we searched for
gene expression networks that correlated with the compound-responsiveness within the cell
line panel. Two ER stress related networks were ranked among the top discoverable
networks by Edge flux (EF) and Process flux (PF) values (Figure S7D)(Komurov et al.,
2012). In addition, an elastic net regression model using basal gene expression data
identified 7 genes (C8G, PSG7, ACOT6, DEPDC5, MMP16, UBR1, and CYP4F22) as
robust indicators of indolotriazine-responsiveness (Figure 7E and S7E). Feature
performance was filtered by a 200X bootstrapping protocol, from which all features were
detected at frequencies > 50%. The sum of the weighted features in this model were used to
predict SW044248-sensitivity from a panel of 38 NSCLC lines outside of the training set.
HCC2429 and H1770 represented the two tails (sensitive and resistant) of the distribution of
predicted IC50s, which was empirically validated with 8-point dose response curves (Figure
7F). 23 of 231 lung adenocarcinomas were within the left-hand tail of the frequency
distribution of elastic net scores suggesting ~10% of tumors contain expression features
consistent with SW044248 sensitivity (Figure S7F).
DISCUSSION
Widespread evidence indicates that acquired vulnerabilities, arising in the course of tumor
evolution, represent key therapeutic intervention opportunities. Starting from within the
context of a single lung adenocarcinoma patient, we identified genetic and chemical
vulnerabilities selectively associated with tumorigenicity. However, the incidence of these
vulnerabilities, within a lineage-restricted panel of NSCLC-derived cell lines, was highly
idiosyncratic. By focusing on perturbations with significant activity in a large cell line panel,
we could begin to detect intervention targets linked to molecular subtypes that specify target
sensitivity and have reasonable frequencies of representation within the lung cancer patient
population.
A robust, but previously unrecognized, genotype/phenotype relationship uncovered by this
approach is the selective addiction of NLRP3 mutant cells to FLIP. FLIP is widely
recognized as a candidate oncology target opportunity due to its role in deflection of
Caspase 8-dependent programmed cell death (Safa and Pollok, 2011), but distinct genetic
settings that specify FLIP-dependence had not been elaborated. NLRP3 triggers
inflammasome assembly and consequent activation of NFκB and cytokine production upon
detection of microbial infection or cellular injury (Bryant and Fitzgerald, 2009; Manji et al.,
2002). It is constitutively expressed in epithelial cells, but in the absence of “danger signals”
is thought to exist in an autoinhibited state (Hu et al., 2013). Of note, mutations in NLRP3
result in persistent cytokine production, and are the causal lesions for CAPS, a group of
congenital autoinflammatory diseases (Hoffman et al., 2001). In light of its role in innate
immune signaling, it is reasonable to suspect that the frequent NLRP3 alterations found in
lung tumors could contribute to tumor growth by inflammatory signal-mediated recruitment
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of stromal cell populations. In this scenario, positive selection for NLRP3 variants that
stimulate production of a protumorigenic niche creates a collateral dependence on FLIP
inhibition of apoptosis. The mechanistic coupling may be direct given recent observations
that the NLRP3 inflammasome can bind and activate caspase 8 (Gringhuis et al., 2012;
Pierini et al., 2012; Sagulenko et al., 2013). Direct chemical inhibition of FLIP is not
currently available, however, a variety of small molecules that inhibit FLIP expression or
enhance FLIP degradation have been reported (Safa and Pollok, 2011; Zhao et al., 2011) and
may represent a path forward for pharmacological targeting of NLRP3 mutant lung cancers.
Detection of oncogenic KRAS-linked vulnerabilities is a high priority, but often
confounding, pursuit in multiple neoplastic settings because of the frequency of
representation of this oncogene in human tumors. Within the context of NSCLC cells, loss
of LKB1 activity together with expression of oncogenic KRAS is required and sufficient to
drive COPI addiction. This genetic interaction reinforces the notion that all KRAS cancers
are not equivalent, and robust mapping of intervention opportunities must account for
distinct collaborative alterations that result in distinct collateral vulnerabilities. The coatamer
complex 1 (COPI) participates in a variety of dynamic membrane trafficking events, and is
well studied for its role in support of retrograde transport (Lee et al., 2004). However we
found that the mechanistic basis of COPI-addiction in the KRASmut/LKB1mut background is
the obligate contribution of this protein complex to lysosome acidification. Chemical or
genetic perturbation of lysosome maturation in KRASmut/LKB1mut cells resulted in
mitochondrial malfunction and cell death. Mitochondrial dependence on lysosomal
maturation was bypassed by supply of cell-permeable TCA cycle substrates, including
pyruvate and α-ketoglutarate. This, together with the observation that KRASmut/LKB1mut
cells displayed signs of elevated lysosomal flux, strongly suggests that this molecular
subtype requires consumption and hydrolysis of extracellular macromolecules for minimal
supply of cellular metabolic intermediates. Recognition of lysosomal function as a context-
dependent metabolic bottleneck is reinforced by three additional recent observations. First,
the coupling of lysosome acidification capacity to mitochondrial health has been defined as
a key determinant of cellular aging in yeast (Hughes and Gottschling, 2012). Second,
pancreas cancer cells mount an adaptive response to glutamine starvation by induction of
macropinocytosis and consequent consumption of extracellular macromolecules as an amino
acid supply route (Commisso et al., 2013). Third, disregulation of mTORC1 drives addiction
to consumption of exogenous desaturated lipids to support endomembrane expansion
(Young et al., 2013). The incidence of co-occurring KRAS and LKB1 mutations in NSCLC
is estimated to be 6% of all lung adenocarcinomas, which corresponds to 5,000 new cancer
patients per year in the USA alone. Establishing KRASmut/LKB1mut mutation status as a
robust indicator of COPI-addiction presents the opportunity to exploit clinical laboratory-
based detection of somatic alterations in these genes as an enrollment biomarker to stratify
patient populations predicted to respond to chemical perturbation of lysosome maturation.
Screening of a large diversity-based collection of synthetic small molecules revealed a
chemical liability in cancer cell lines that share distinct gene expression features. While the
target of this compound remains to be defined, the mode-of-action appears to be through
selective mobilization of the unfolded protein response and consequent cell death. Of
interest, a relatively large but highly selective cohort is responsive to the indolotriazine
SW044248 (24% of cell lines tested). Thus SW0044248 can be described as a chemical
discriminator of a distinct NSCLC subtype. If indolotriazine sensitivity is preserved in the in
vivo setting, this chemical discriminator becomes a lead for therapeutically relevant
pharmacological characterization of discrete vulnerabilities within this subtype.
In summary, cell-based exploration of lung cancer intervention opportunities can be a rich
source of target discovery given sufficient commonality of sensitivity and resolution of
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molecular correlates. Starting with disease-cell-selective vulnerabilities present in isolates
from a single lung cancer patient, two distinct molecular targets were identified, linked to
two distinct genetic lesions, which together are represented in over 25% of lung
adenocarcinoma patients. In addition, a chemically-defined vulnerability was identified that
is associated with an expression-based biomarker estimated to occur in 10% of lung cancer
patients.
EXPERIMENTAL PROCEDURES
Materials, procedures and computational analysis including deep sequencing, high
throughput screening and associated data processing and analysis, mouse xenograft studies,
mitochondrial respiratory potential, metabolic flux, pharmacokinetic analysis, and elastic net
regression modeling and other statistical processing protocols, are detailed in an Extended
Experimental Procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Systematic isolation of context-dependent vulnerabilities in NSCLC
• NLRP3 mutations drive addiction to FLIP expression
• Lysosome maturation is a metabolic bottleneck for KRAS/LKB1 tumors
• Selective sensitivity to an indolotriazine discriminates a NSCLC expression
subtype
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Figure 1. Public and private genetic vulnerabilities
A. Schematic of discovery platform for target/biomarker relationships. B. Genome-wide
view of relative genomic DNA content, mRNA content, and RNAi toxicity in HCC4017 by
two independent siRNA libraries (orange indicates Z < −3). C. Penetrance of the HCC4017
RNAi hits in 22 NSCLC lines. D. Gene ontology (%) of the private (N = 30; response in 1–2
lines) and public (N=48; response in > 2 lines) RNAi hits. Subgraphs from the PPI network
(see Figure S1H) are displayed in the boxes. See also Figure S1, Table S1, S2, and S3, and
Data S1, S2, S4, S5, and S6.
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Figure 2. Context-selective FLIP-addiction
A. Barplots indicate toxicity of CFLAR depletion in the most sensitive (relative viability <
0.3) and most resistant NSCLC cell lines (> 0.9), and two nontumorigenic lines. Heatmap
indicates the gene expression signature with the maximal bimodal distribution between
groups. SMAC responsiveness is indicated as determined by LD50 (supplemental table 5).
Error bars indicate +/− standard deviation from the mean (SDM, N = 3). B. The indicated
siRNAs were tested for consequences on siCFLAR dependent toxicity within each of the
CFLAR-dependent cell lines. Error bars as in A. C. The indicated siRNAs were tested for
consequences on SMAC mimetic induced toxicity within each of the SMAC mimetic-
responsive cell lines. Error bars as in A. D. Pfam-A domain structure of NALP3 and maps of
somatic mutations found. E. Empirical CDF plot of PYCARD expression from lung
adenocarcinomas with or without highly deleterious mutations in NLRP3 (TCGA). F.
Consequence of NLRP3 depletion on CFLAR dependency ** P < 0.01, * P < 0.05 by two-
sided unpaired Student’s t-test. siRNA-mediated NLRP3 gene depletion is indicated as
measured by qPCR (right). Error bars as in A. G. Tumor weights (g) following treatment
with either control or CFLAR siRNAs. Error bars indicate +/− standard error from the mean
(SEM). *P = 0.026 by Wilcoxon rank sum test. See also Figure S2 and Table S4.
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Figure 3. KRASmut/LKB1mut mutation status specifies Coatomer 1 addiction
A. RNAi toxicity profiles of the most sensitive and most resistant NSCLC lines to siRNA
pools targeting COPI are shown. Mutation status of the KRAS and LKB1 is indicated, M
(mutant) or wt (wild type). B. The indicated cell lines were transfected with the indicated
siRNAs in 96-well plates, and incubated for 48 hours followed by transfer to 24-well plates
and incubation for an additional 6 days. Crystal violet stained wells are shown. The
immunoblot indicates persistence of target depletion in HBEC3 at the 8-day timepoint. C.
The consequence of COPI depletion on HCC4017 colony formation in soft-agar is shown.
Error bars indicate +/− SDM, N = 3. D. Therapeutic effects of ARCN1 siRNA in an
orthotopic lung adenocarcinoma model (A549). Error bars indicate +/− SEM. One-sided
Wilcoxon rank sum test p-values were all < 0.01 (**). E. Consequence of AICAR on AMPK
activation in two COPI dependent (HCC4017 and H460) and two independent (H2009 and
H441) KRAS mutant lines. F. Additional NSCLC lines from outside the test panel, with
known KRASmut/LKB1mut status, were assayed for BrdU incorporation to detect
consequences of COPI depletion on proliferation as shown. Error bars as in C. G.
Consequence of LKB1/COPI codepletion in KRAS mutant cells. Immunoblots indicate
target depletion. Error bars as in C. See also Figure S3.
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Figure 4. Oncogenic KRAS together with LKB1 loss is sufficient to induce COPI-addiction
A. Steady-state accumulation of the indicated proteins and phospho-proteins was assessed
by immunoblot of whole-cell lysates from the indicated HBEC30KT derivatives. B.
Representative H&E images, of xenograft tumors formed upon subcutaneous inoculation of
HBEC30KT-shTP53/KRASG12V/shLKB1, indicating mixed adenosquamous (top) and
squamous (bottom) histology. C. Toxicity profile of the HCC4017 siRNA hits within the
HBEC30KT progression series. The 17/85 siRNAs selectively toxic to the KRASmut/
LKB1mut cell lines are shown. D. Viability distributions of siRNA pools from 4C across 18
NSCLC lines with the indicated genotypes. Boxplots whiskers extend to +/− 1.5 IQR. Two-
sided KS test p-values for all pair comparisons against the double mutants are less than E-10
(**). E. The indicated cells were stained with crystal violet as in Figure 3B. Immunoblot
indicates persistence of target depletion in resistant cells at the 8-day timepoint. See also
Figure S4.
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Figure 5. The KRASmut/LKB1mut NSCLC subtype mirrors the mesenchymal (Claudin-low)
subtype of triple negative breast cancer
A. Top 100 differentially regulated genes as identified by signal to noise ratio between COPI
dependent and independent cancer lines. Claudin-low signature genes are indicated in red
for upregulated (10/437) and green (19/370) for downregulated genes, hypergeometric p <
6.7 X 10E-16. B. Selective consequence of ARCN1 depletion on the viability of breast
cancer cell lines. Error bars indicate +/− SDM, N = 3. C. Patient cohorts with the COPI-
addicted gene expression signature (Cluster I) show poor prognosis. Kaplan-Meier plots are
shown for overall (left) and cancer free survival (right) of the patient populations
dichotomized as described in Figure S5C. p-values are log-rank test. D.E.F. Consequence of
codepletion of IL6 (D), IL6R (E), or exposure to Let-7 family of miRNA mimics (F) on
siRNA toxicity of indicated COPI subunits. Error bars as in B. G.H. IL-6 secretion was
measured by ELISA post-transfection of the indicated siRNAs in the indicated cell lines.
Values were normalized to cell number. ** P < 0.01, * P < 0.05, two-sided unpaired
Student’s t-test, error bars as in B. See also Figure S5 and Table S5.
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Figure 6. Lysosomal maturation is required to support mitochondrial oxidative phosphorylation
and survival of KRASmut/LKB1mut NSCLC cells in vitro and in vivo
A. Compound mimic screen. The indicated compounds were tested over 11 doses (2X serial
dilution) for toxicity in HCC4017 and KRASmut/LKB1mut lines (N=6) versus HBEC30KT
and others (N=14). AUC was estimated by the sum of % viability over testing doses. One-
sided two-sample K-S tests were performed to discriminate compounds with selective
activity. K-S test p-values in negative log scale were used to generate the plot. B. HCC44
cells, transfected with the indicated siRNAs, were stained with the indicated dyes and
antibodies. 71% of siARCN1 cells were Lysotracker negative versus 3.0% of siNC cells, p-
value < 2.2E-16, Fisher’s exact test. C. Confocal imaging of mitochondrial morphology after
42 hour exposure to vATPase inhibitors. 92% bafA-treated and 85% saliPhe-treated cells
had dysmorphic mitochondria versus 2.7% with DMSO, p-value < 2.2E-16 for both,
Fisher’s exact test. D. Oxygen consumption rates (OCR) of HCC44 cells exposed to the
indicated compounds. Error bars indicate +/− SDM, N = 3. E. Mass isotopomer analysis of
citrate in HCC44 cells cultured with D[U-13C]glucose and unlabeled glutamine (left for each
cell line) or L[U-13C]glutamine and unlabeled glucose (right for each cell line) after
exposure to 10 nM BafA or 1 μM SaliPhe for 16 hours. **P < 0.01, * P< 0.05, two-sided t-
test, error bars as in B. F. Live cell images obtained as in 6B and 6C. G. As in 6D except
Kim et al. Page 20
Cell. Author manuscript; available in PMC 2014 October 24.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
that HCC44 cells were transfected with the indicated siRNAs prior to the assay. 93% of
siATP6V1B2 cells had dysmorphic mitochondria versus 0% of siNC cells, p-value <
2.2E-16, Fisher’s exact test, error bars as in B. H. Caspase-3 and 7 activity was measured
after exposure of HCC4017 to DMSO or bafA (5 nM) for 48 hours together with methyl
pyruvate (8 mM), dimethyl-2-oxoglutarate (MOG, 5 mM), or water (CTL). Error bars as in
B. I. Indicated siRNAs were tested for consequences on bafA (10 nM) dependent toxicity in
HCC44 and A549. Cells were exposed to bafA 48 hours post transfection. Error bars as in B.
J. 2.5 × 106 HCC4017 cells were injected subcutaneously into NOD/SCID mice. Tumor
volume vs. days post tumor injection is displayed for mice treated with saliPhe, or saline as
indicated. Error bars indicate +/− SEM. See also Figure S6 and Table S5.
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Figure 7. A gene expression model predicts sensitivity to an indolotriazine
A. AC50 for the HCC4017-selective synthetic indolotriazine derivative against 74 additional
NSCLC cell lines and immortalized HBECs. B. Top 10 differential gene expression
responses to SW044248 (2 μM, 6 hours) in HCC4017 parental (P) and resistant clones (RS,
RW) as detected by RNA-seq (ANOVA P < 0.005, Data S7). C. Relative accumulation of
CHOP, IRE1α, and BiP proteins upon exposure of HCC4017 for the indicated times. D. As
in 7C except using a 24 hr exposure with indicated cell lines. E. Predictive basal gene
expression features for SW044248 sensitivity in 48 NSCLCs by elastic net regression
modeling. Compound response (AC50) is indicated in the top row. Predictive gene
expression features (normalized by sample median) across 48 NSCLCs are shown. Bar plot
on the left indicates the average weight for the corresponding feature as determined from a
200X bootstrapping analysis. Frequency of feature occurrence is shown in parenthesis. F.
Dose response curves for a predicted sensitive cell line, HCC2429, and a predicted resistant
cell line H1770, based on the expression signature-derived scoring function. Error bars
indicate +/− SDM, n = 3. See also Figure S7 and Data S3–1, S3–2, S3–3, and S7.
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